ClinicalTrials.gg
CompletedNCT02963935SCALE™ IBTUpdated Mar 11, 2020Results posted

Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting

A Phase 3 interventional study of liraglutide and placebo in Metabolism and Nutrition Disorder and Obesity, sponsored by Novo Nordisk A/S. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-11.

Primary conditionObesityRegistry: Nutrition DisordersReclassifiedWhy we changed it
Registry
Nutrition Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Nutrition Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
282
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 79 studies testing liraglutide in Obesity — 7 open to participants now, 9 under way, 2 of them phase 3. Liraglutide · Obesity.

Enrollment
13th of 79
282 · median 70
Started
2017
with 11 others
Phase 3
17 of 79
1 open now
Registered
34th of 79
by date
Lead sponsor
16 of 79
Novo Nordisk A/S

Among the 79 studies testing liraglutide in Obesity, this one is the 13th largest by enrollment, is one of 12 that started in 2017, is one of 17 in phase 3, and was the 34th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

7 of the 79 studies testing liraglutide in Obesity are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies testing liraglutide in Obesity, or all of them as a file.
02

Study summary

This trial is conducted in the United States of America (USA). The purpose of the trial is to investigate the effect and safety of liraglutide 3.0 mg as an adjunct to intensive behaviour therapy for obesity in a non-specialist setting (IBT-CMS: Intensive Behaviour Therapy for obesity in a primary care setting according to Centers for Medicare \& Medicaid Services (CMS) visit schedule).

03

Conditions studied

  • Metabolism and Nutrition Disorder
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 282 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nutrition Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
  • above or equal to 30 kg/m\^2
  • Male or female, age 18 years or older at the time of signing informed consent

Exclusion criteria

Exclusion Criteria:

  • (glycosylated ) above or equal to 6.5% (at screening visit), or diagnosis of type 1 or type 2 diabetes mellitus
  • Recent history of cardiovascular disease (myocardial infarction or stroke within the past 6 months), severe congestive heart failure ( class III, IV), or second degree or greater heart block
  • Personal or family history of Medullary Thyroid Carcinoma (MTC), or Multiple Endocrine Neoplasia type 2 (MEN2)
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using an adequate method (adequate contraceptive measure as required by local regulation or practice)
  • Use in past 90 days of medications known to induce significant weight loss (e.g., prescription weight loss medications) or weight gain (e.g., chronic use of oral , second generation antipsychotics)
  • History of pancreatitis (acute or chronic)
  • History of major depressive disorder within the past 2 years
  • Any lifetime history of a suicide attempt
  • Inadequately treated blood pressure defined as Grade 3 hypertension or higher (Systolic above or equal to 180 mmHg or diastolic above or equal to 110 mmHg)
  • History of (except for non-melanoma skin cancer) within the past 5 years
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
282 participants (actual)

Study arms

  • Experimental
    Liraglutide

    Drug: liraglutide · Behavioral: CMS Intensive Behavior Therapy

  • Placebo comparator
    Placebo

    Drug: placebo · Behavioral: CMS Intensive Behavior Therapy

Interventions

  • Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg

  • Drugplacebo

    Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg

  • BehavioralCMS Intensive Behavior Therapy

    Intensive Behaviour Therapy for obesity

07

What researchers measure

Primary outcomes

  1. Change in Body Weight (%)

    Observed mean change in body weight from baseline (week 0) to week 56 was evaluated for two different observation periods. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which subjects are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs). The test of superiority of liraglutide to placebo for the treatment policy estimand was tested in a hierarchical manner for the two primary and the consequent 7 confirmatory secondary endpoints presented.

    Time frame: Week 0, week 56

  2. Proportion of Subjects Losing at Least 5% of Baseline Body Weight at Week 56

    The estimated mean percentage of subjects losing at least 5% of baseline body weight at week 56 is presented. The endpoint was evaluated based on in-trial data and on-drug data.

    Time frame: Week 56

Secondary outcomes

  1. Proportion of Subjects Losing More Than 10% of Baseline Body Weight at Week 56

    The estimated mean percentage of subjects losing more than 10% of baseline body weight at week 56 is presented. The endpoint was evaluated based on in-trial data and on-drug data.

    Time frame: Week 56

  2. Proportion of Subjects Losing More Than 15% of Baseline Body Weight at Week 56

    The estimated mean percentage of subjects losing more than 15% of baseline body weight at week 56 is presented. The endpoint was evaluated based on in-trial data and on-drug data.

    Time frame: Week 56

  3. Proportion of Subjects Losing 4% or More of Baseline Body Weight

    The estimated mean percentage of subjects losing 4% or more of baseline body weight at week 16 is presented. The endpoint was evaluated for treatment policy estimand (in-trial data).

    Time frame: Week 16

  4. Change in Waist Circumference (cm)

    Observed mean change from baseline in waist circumference. The endpoint was evaluated based on in-trial data and on-drug data.

    Time frame: Week 0, week 56

  5. Change in Short Form-36 (SF-36) v2.0 Acute, Physical Functioning Score

    SF-36 is a 36-item patient-reported survey of patient health that measures the subject's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in SF-36 physical functioning score is presented. A positive change score indicates an improvement since baseline. The endpoint was evaluated based on in-trial data and on-drug data.

    Time frame: Week 0, week 56

  6. Change in IWQoL-Lite for CT, Physical Function Domain (5-items) Score

    Observed mean change in Impact of Weight on Quality of Life-Lite for Clinical Trials Version (IWQoL-Lite for CT ) score. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. The endpoint was evaluated based on in-trial data and on-drug data.

    Time frame: Week 0, week 56

  7. Change in Six Minutes Walking Distance Test (6MWT)

    Observed mean change from baseline in 6 minutes walking distance test. The 6MWT is a common test of functional exercise capacity that assesses the distance a subject can walk in 6 minutes. The endpoint was evaluated based on in-trial data and on-drug data.

    Time frame: Week 0, week 56

  8. Change From Baseline in HbA1c (%)

    Observed mean change from baseline to week 56 in glycosylated haemoglobin (HbA1c). Results based on FAS in-trial data is presented.

    Time frame: Week 0, week 56

  9. Change From Baseline in FPG (mg/dL)

    Observed mean change from baseline (week 0) in fasting plasma glucose (FPG). Results based on FAS in-trial data is presented.

    Time frame: Week 0, week 56

  10. Change From Baseline sBP (mmHg)

    Observed mean change in systolic blood pressure from baseline to week 56.

    Time frame: Week 0, week 56

  11. Change From Baseline dBP (mmHg)

    Observed mean change from baseline (week 0) to week 56 in diastolic blood pressure (dBP). Results based on FAS in-trial data is presented.

    Time frame: Week 0, week 56

  12. Change From Baseline in Lipids -Total Cholesterol

    Observed mean change from baseline (week 0) to week 56 in total cholesterol (TC). Results based on FAS in-trial data is presented.

    Time frame: Week 0, week 56

  13. Change From Baseline in Lipids - LDL Cholesterol

    Observed mean change from baseline in low density cholesterol (LDL) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.

    Time frame: Week 0, week 56

  14. Change From Baseline in Lipids - HDL Cholesterol

    Observed mean change from baseline in high density (HDL) cholesterol from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.

    Time frame: Week 0, week 56

  15. Change From Baseline in Lipids - VLDL Cholesterol

    Observed mean change from baseline in very low density cholesterol (VLDL) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.

    Time frame: Week 0, week 56

  16. Change From Baseline in Lipids - TG

    Observed mean change from baseline in triglyceride (TG) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.

    Time frame: Week 0, week 56

  17. Change From Baseline in Lipids - FFA

    Observed mean change from baseline in free fatty acids (FFA) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.

    Time frame: Week 0, week 56

  18. Change in Short Form-36 v2.0 Acute (SF-36) (Subdomains)

    SF-36 is a 36-item patient-reported survey of patient health that measures the subject's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in in the sub-domain scores is presented. A positive change score indicates an improvement since baseline. Results are evaluated based on in-trial data.

    Time frame: Week 0, week 56

  19. Change in Short Form-36 v2.0 Acute (SF-36) (Physical Component Summary (PCS))

    Observed mean change from baseline (week 0) to week 56 in short form 36 v2.0 acute domain physical component summary (PCS). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in SF-36 physical component summary (PCS) score is presented. A positive change score indicates an improvement since baseline. The endpoint was evaluated based on in-trial data and on-drug data.

    Time frame: Week 0, week 56

  20. Change in Short Form-36 v2.0 Acute (SF-36) (Mental Component Summary (MCS)

    Observed mean change from baseline (week 0) to week 56 in short form 36 v2.0 acute domain mental component summary (MCS). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in SF-36 mental component summary is presented. A positive change score indicates an improvement since baseline. The endpoint was evaluated based on in-trial data and on-drug data.

    Time frame: Week 0, week 56

  21. Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Pain/Discomfort Domain Score

    Observed mean change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT) domain pain and discomfort. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. Results based on FAS in-trial data is presented.

    Time frame: Week 0, week 56

  22. Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Psychosocial Domain Score

    Observed mean change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT) psychosocial domain. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. Results based on FAS in-trial data is presented.

    Time frame: Week 0, week 56

  23. Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Total Score

    Observed mean change from baseline (week 0) to week 56 in IWQoL-Lite for CT total score. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. Results based on FAS in-trial data is presented.

    Time frame: Week 0, week 56

  24. Change in Weight Related Sign and Symptom (WRSS) Measure, Total Score

    Observed mean change from baseline (week 0) to week 56 in WRSS measure, total score. The WRSS measures the presence and bothersome associated with weight-related symptoms. The WRSS questionnaire was not validated until after database lock. Therefore the total score couldn't be calculated and the supportive secondary endpoint "Weight related sign and symptom (WRSS) measure, total score" couldn't be analysed.

    Time frame: Week 0, week 56

  25. Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 4.3 T-score Points Increase From Baseline in SF-36 Physical Functioning Score

    Percentage of subjects who achieved ≥ 4.3 T-score points increase from baseline in SF-36 physical functioning score at week 56 is presented. Results based on FAS in-trial data is presented.

    Time frame: Week 56

  26. Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 3.8 T-score Points Increase From Baseline in SF-36 Physical Component Score

    Percentage of subjects who achieved ≥ 3.8 T-score points increase from baseline in SF-36 physical component score at week 56 is presented. Results based on FAS in-trial data is presented.

    Time frame: Week 56

  27. Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 4.6 T-score Points Increase From Baseline in SF-36 Mental Component Score

    Percentage of subjects who achieved ≥ 4.6 T-score points increase from baseline in SF-36 mental component score at week 56 is presented. Results based on FAS in-trial data is presented.

    Time frame: Week 56

  28. Responder Definition Value for IWQoL-Lite for CT Physical Function Domain (5-items) Score

    Responder definition value for IWQoL-Lite for CT physical function domain (5-items) score' was defined as '≥ 20 responder definition value for IWQoL-Lite for CT physical function domain (5-items) score. Percentage of subjects considered IWQoL-Lite for CT physical function domain score responders (increase of ≥20 points) at week 56 is presented. Results based on FAS in-trial data is presented.

    Time frame: Week 56

  29. Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Trial Product

    Adherence to trial product is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to trial product is presented.

    Time frame: Week 0, week 56

  30. Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet

    Adherence to caloric diet is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to caloric diet is presented.

    Time frame: Week 0, week 56

  31. Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Physical Activity

    Adherence to physical activity is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to physical activity is presented.

    Time frame: Week 0, week 56

  32. Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet and Physical Activity

    Adherence to caloric diet and physical activity is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to caloric diet and physical activity is presented.

    Time frame: Week 0, week 56

  33. Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet, Physical Activity and Trial Product

    Adherence to caloric diet, physical activity and trial product is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to caloric diet, physical activity and trial product is presented.

    Time frame: Week 0, week 56

  34. AEs From Randomisation Until and Including the Follow-up Period

    Number of adverse events from randomisation to until the end of the post-treatment follow-up period (30 days). Results based on SAS on-drug data is presented.

    Time frame: Week 0 to week 56+30 days

  35. Change in Physical Examination

    Observed change from baseline to week 56 in physical examination are categorised under parameters namely abdomen, gastrointestinal system, cardiovascular system, central and peripheral nervous system, general appearence, head, ears, eyes, nose, throat and neck, lymph node palpation, musculoskeletal system, respiratory system, skin and thyroid gland. The percentage of subjects assessed as normal, abnormal not clinically significant and abnormal clinically significant at baseline and week 56 is presented.

    Time frame: Week 1, week 56

  36. Change in Resting Pulse

    Observed mean change in pulse rate measured at resting position is presented.

    Time frame: Week 0, week 56

  37. Change in ECG

    The ECGs were interpreted by the investigator at baseline (week -1) and week 56 and categorised as normal, abnormal NCS or abnormal CS. Number of subjects in each ECG category at baseline and week 56 are presented.

    Time frame: Week -1, week 56

  38. Change in Laboratory Measurements: Haematology (Haemoglobin Blood)

    Observed mean change from baseline in haematological parameter blood haemoglobin.

    Time frame: Week 0, week 56

  39. Change in Laboratory Measurements: Haematology (Haematocrit Blood)

    Observed mean change from baseline in haematological parameter blood haematocrit. Haematocrit is presented as the percentage of red blood cells in total blood. Results based on SAS on-drug data is presented.

    Time frame: Week 0, week 56

  40. Change in Laboratory Measurements: Haematology (Erythrocytes)

    Observed mean change from baseline in haematological parameter - erythrocytes.

    Time frame: Week 0, week 56

  41. Change in Laboratory Measurements: Haematology (Thrombocytes and Leukocytes)

    Observed mean change from baseline in haematological parameters - thrombocytss and leukocytes.

    Time frame: Week 0, week 56

  42. Change in Laboratory Measurements: Biochemistry (Albumin)

    Observed mean change from baseline in biochemical parameter - albumin. Results based on SAS on-drug data is presented.

    Time frame: Week 0, week 56

  43. Change in Laboratory Measurements: Biochemistry (Alkaline Phosphatase, Alanine Aminotransferase, Amylase, Aspartate Aminotransferase and Lipase)

    Observed mean change from baseline in biochemical parameters - alkaline phosphatase, alanine aminotransferase, amylase, aspartate aminotransferase and lipase. Results based on SAS on-drug data is presented.

    Time frame: Week 0, week 56

  44. Change in Laboratory Measurements: Biochemistry (Bilirubin and Creatinine)

    Observed mean change from baseline in biochemical parameters - bilirubin and creatinine. Results based on SAS on-drug data is presented.

    Time frame: Week 0, week 56

  45. Change in Laboratory Measurements: Biochemistry (Total Calcium, Pottassium, Sodium and Urea)

    Observed mean change from baseline in biochemical parameters - total calcium, pottassium, sodium and urea. Results based on SAS on-drug data is presented.

    Time frame: Week 0, week 56

  46. Change in Laboratory Measurements: Biochemistry (C-reactive Protein and Uric Acid)

    Observed mean change from baseline in biochemical parameters - high sensitive c-reactive protein and uric acid. Results based on SAS on-drug data is presented.

    Time frame: Week 0, week 56

  47. Change in Laboratory Measurements: Biochemistry (Glomerular Filtration Rate, Serum)

    Observed mean change from baseline in biochemical parameters - estimated glomerular filtration rate. Serum GFR is estimated using MDRD formula . Results based on SAS on-drug data is presented.

    Time frame: Week 0, week 56

  48. Change in Laboratory Measurements: Biochemistry (Calcitonin)

    Observed mean change from baseline in biochemical parameter - calcitonin. Results based on SAS on-drug data is presented.

    Time frame: Week 0, week 56

  49. Change in Laboratory Measurements: Biochemistry (Thyroid Stimulating Hormone)

    Observed mean change from baseline in biochemical parameters - thyroid stimulating hormone. Results based on SAS on-drug data is presented.

    Time frame: Week 0, week 56

08

Results

Posted Jul 30, 2019

Participant flow

The trial was conducted at 17 sites in the United States.

Participant flow — Overall Study
MilestoneLiraglutide 3.0 mgPlacebo
Started142140
Completed114103
Not completed2837
Withdrew: Adverse event126
Withdrew: Protocol violation21
Withdrew: Lack of efficacy02
Withdrew: Lost to follow-up16
Withdrew: Unclassified1322

Outcome measures

PrimaryChange in Body Weight (%)

Observed mean change in body weight from baseline (week 0) to week 56 was evaluated for two different observation periods. In-trial observation period: the uninterrupted time interval from the date of randomisation until and including the date of the follow-up visit or date of last contact. On-drug observation period: includes all time intervals in which subjects are considered to be on treatment from the date of first trial product administration to 7 days (or 14 days for AEs) after the final trial product administration, excluding potential off-treatment time intervals triggered by at least 7 consecutive missed doses (or 14 consecutive missed doses for AEs). The test of superiority of liraglutide to placebo for the treatment policy estimand was tested in a hierarchical manner for the two primary and the consequent 7 confirmatory secondary endpoints presented.

Time frame:
Week 0, week 56
Reported as:
Mean · percent change
Change in Body Weight (%)
percent changeLiraglutide 3.0 mgPlacebo
In-trial observation period-7.4 ± 7.9-4.0 ± 7.4
On-drug observation period-9.1 ± 7.4-4.8 ± 7.6
Statistical analysis
  • Liraglutide 3.0 mg vs Placebo · ANCOVA · p = 0.0003 · Treatment difference: -3.45 · 95% CI -5.31 to -1.59Liraglutide 3.0 mg - placebo
  • Liraglutide 3.0 mg vs Placebo · Mixed models repeated measurement (MMRM) · p = 0.0000 · Treatment difference: -4.59 · 95% CI -6.54 to -2.64Liraglutide 3.0 mg - placebo
PrimaryProportion of Subjects Losing at Least 5% of Baseline Body Weight at Week 56

The estimated mean percentage of subjects losing at least 5% of baseline body weight at week 56 is presented. The endpoint was evaluated based on in-trial data and on-drug data.

Time frame:
Week 56
Reported as:
Number · percentage of participants
Proportion of Subjects Losing at Least 5% of Baseline Body Weight at Week 56
percentage of participantsLiraglutide 3.0 mgPlacebo
In-trial observation period61.4738.82
On-drug observation period64.0838.57
Statistical analysis
  • Liraglutide 3.0 mg vs Placebo · Regression, Logistic · p = 0.0003 · Odds ratio (or): 2.51 · 95% CI 1.53 to 4.14Liraglutide 3.0 mg/Placebo
  • Liraglutide 3.0 mg vs Placebo · Mixed models repeated measurement (MMRM) · p = 0.0000 · Odds ratio (or): 2.84 · 95% CI 1.75 to 4.61Liraglutide 3.0 mg/placebo
SecondaryProportion of Subjects Losing More Than 10% of Baseline Body Weight at Week 56

The estimated mean percentage of subjects losing more than 10% of baseline body weight at week 56 is presented. The endpoint was evaluated based on in-trial data and on-drug data.

Time frame:
Week 56
Reported as:
Number · percentage of participants
Proportion of Subjects Losing More Than 10% of Baseline Body Weight at Week 56
percentage of participantsLiraglutide 3.0 mgPlacebo
In-trial observation period30.4519.75
On-drug observation period33.8019.29
Statistical analysis
  • Liraglutide 3.0 mg vs Placebo · Regression, Logistic · p = 0.0469 · Odds ratio (or): 1.78 · 95% CI 1.01 to 3.14Liraglutide 3.0 mg/Placebo
  • Liraglutide 3.0 mg vs Placebo · Mixed models repeated measurement (MMRM) · p = 0.0063 · Odds ratio (or): 2.14 · 95% CI 1.24 to 3.69Liraglutide 3.0 mg/placebo
SecondaryProportion of Subjects Losing More Than 15% of Baseline Body Weight at Week 56

The estimated mean percentage of subjects losing more than 15% of baseline body weight at week 56 is presented. The endpoint was evaluated based on in-trial data and on-drug data.

Time frame:
Week 56
Reported as:
Number · percentage of participants
Proportion of Subjects Losing More Than 15% of Baseline Body Weight at Week 56
percentage of participantsLiraglutide 3.0 mgPlacebo
In-trial observation period18.118.92
On-drug observation period20.428.57
Statistical analysis
  • Liraglutide 3.0 mg vs Placebo · Regression, Logistic · p = 0.0311 · Odds ratio (or): 2.26 · 95% CI 1.08 to 4.74Liraglutide 3.0 mg/Placebo
  • Liraglutide 3.0 mg vs Placebo · Mixed models repeated measurement (MMRM) · p = 0.0060 · Odds ratio (or): 2.74 · 95% CI 1.33 to 5.62Liraglutide 3.0 mg/placebo
SecondaryProportion of Subjects Losing 4% or More of Baseline Body Weight

The estimated mean percentage of subjects losing 4% or more of baseline body weight at week 16 is presented. The endpoint was evaluated for treatment policy estimand (in-trial data).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Proportion of Subjects Losing 4% or More of Baseline Body Weight
percentage of participantsLiraglutide 3.0 mgPlacebo
Proportion of Subjects Losing 4% or More of Baseline Body Weight78.7352.70
Statistical analysis
  • Liraglutide 3.0 mg vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 3.32 · 95% CI 1.93 to 5.72Liraglutide 3.0 mg/placebo
SecondaryChange in Waist Circumference (cm)

Observed mean change from baseline in waist circumference. The endpoint was evaluated based on in-trial data and on-drug data.

Time frame:
Week 0, week 56
Reported as:
Mean · cm
Change in Waist Circumference (cm)
cmLiraglutide 3.0 mgPlacebo
In-trial observation period-9.27 ± 9.22-6.91 ± 8.22
On-drug observation period-10.46 ± 9.22-7.24 ± 8.67
Statistical analysis
  • Liraglutide 3.0 mg vs Placebo · ANCOVA · p = 0.0063 · Treatment difference: -2.72 · 95% CI -4.68 to -0.77Liraglutide 3.0 mg - placebo
  • Liraglutide 3.0 mg vs Placebo · Mixed model repeated measurements (MMRM) · p = 0.0020 · Treatment difference: -3.45 · 95% CI -5.62 to -1.28Liraglutide 3.0 mg - placebo
SecondaryChange in Short Form-36 (SF-36) v2.0 Acute, Physical Functioning Score

SF-36 is a 36-item patient-reported survey of patient health that measures the subject's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in SF-36 physical functioning score is presented. A positive change score indicates an improvement since baseline. The endpoint was evaluated based on in-trial data and on-drug data.

Time frame:
Week 0, week 56
Reported as:
Mean · Scores on a scale
Change in Short Form-36 (SF-36) v2.0 Acute, Physical Functioning Score
Scores on a scaleLiraglutide 3.0 mgPlacebo
In-trial observation period3.55 ± 6.984.21 ± 6.85
On-drug observation period4.03 ± 6.494.77 ± 6.03
Statistical analysis
  • Liraglutide 3.0 mg vs Placebo · ANCOVA · p = 0.8137 · Treatment difference: 0.16 · 95% CI -1.19 to 1.52Liraglutide 3.0 mg - placebo
  • Liraglutide 3.0 mg vs Placebo · Mixed model repeated measurements (MMRM) · p = 0.8053 · Treatment difference: 0.16 · 95% CI -1.12 to 1.43Liraglutide 3.0 mg- placebo
SecondaryChange in IWQoL-Lite for CT, Physical Function Domain (5-items) Score

Observed mean change in Impact of Weight on Quality of Life-Lite for Clinical Trials Version (IWQoL-Lite for CT ) score. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. The endpoint was evaluated based on in-trial data and on-drug data.

Time frame:
Week 0, week 56
Reported as:
Mean · Scores on a scale
Change in IWQoL-Lite for CT, Physical Function Domain (5-items) Score
Scores on a scaleLiraglutide 3.0 mgPlacebo
In-trial observation period13.5 ± 21.415.5 ± 23.0
On-drug observation period15.2 ± 21.417.5 ± 21.4
Statistical analysis
  • Liraglutide 3.0 mg vs Placebo · ANCOVA · p = 0.6916 · Treatment difference: 0.87 · 95% CI -3.41 to 5.14Liraglutide 3.0 mg - placebo
  • Liraglutide 3.0 mg vs Placebo · Mixed models repeated measurements (MMRM · p = 0.5572 · Treatment difference: 1.25 · 95% CI -2.95 to 5.45Liraglutide 3.0 mg - placebo
SecondaryChange in Six Minutes Walking Distance Test (6MWT)

Observed mean change from baseline in 6 minutes walking distance test. The 6MWT is a common test of functional exercise capacity that assesses the distance a subject can walk in 6 minutes. The endpoint was evaluated based on in-trial data and on-drug data.

Time frame:
Week 0, week 56
Reported as:
Mean · meter
Change in Six Minutes Walking Distance Test (6MWT)
meterLiraglutide 3.0 mgPlacebo
In-trial observation period47 ± 5949 ± 69
On-drug observation period53 ± 6151 ± 69
Statistical analysis
  • Liraglutide 3.0 mg vs Placebo · ANCOVA · p = 0.6986 · Treatment difference: 3.12 · 95% CI -12.68 to 18.92Liraglutide 3.0 mg - placebo
  • Liraglutide 3.0 mg vs Placebo · Mixed model repeated measurements (MMRM) · p = 0.3700 · Treatment difference: 7.66 · 95% CI -9.15 to 24.48Liraglutide 3.0 mg - placebo
SecondaryChange From Baseline in HbA1c (%)

Observed mean change from baseline to week 56 in glycosylated haemoglobin (HbA1c). Results based on FAS in-trial data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · percentage
Change From Baseline in HbA1c (%)
percentageLiraglutide 3.0 mgPlacebo
Change From Baseline in HbA1c (%)-0.2 ± 0.3-0.1 ± 0.2
SecondaryChange From Baseline in FPG (mg/dL)

Observed mean change from baseline (week 0) in fasting plasma glucose (FPG). Results based on FAS in-trial data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · mg/dL
Change From Baseline in FPG (mg/dL)
mg/dLLiraglutide 3.0 mgPlacebo
Change From Baseline in FPG (mg/dL)-4.04 ± 9.59-0.28 ± 11.46
SecondaryChange From Baseline sBP (mmHg)

Observed mean change in systolic blood pressure from baseline to week 56.

Time frame:
Week 0, week 56
Reported as:
Mean · mmHg
Change From Baseline sBP (mmHg)
mmHgLiraglutide 3.0 mgPlacebo
Change From Baseline sBP (mmHg)-2 ± 14-1 ± 13
SecondaryChange From Baseline dBP (mmHg)

Observed mean change from baseline (week 0) to week 56 in diastolic blood pressure (dBP). Results based on FAS in-trial data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · mmHg
Change From Baseline dBP (mmHg)
mmHgLiraglutide 3.0 mgPlacebo
Change From Baseline dBP (mmHg)-1 ± 11-1 ± 10
SecondaryChange From Baseline in Lipids -Total Cholesterol

Observed mean change from baseline (week 0) to week 56 in total cholesterol (TC). Results based on FAS in-trial data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · mmol/L
Change From Baseline in Lipids -Total Cholesterol
mmol/LLiraglutide 3.0 mgPlacebo
Change From Baseline in Lipids -Total Cholesterol-0.01 ± 0.590.00 ± 0.77
SecondaryChange From Baseline in Lipids - LDL Cholesterol

Observed mean change from baseline in low density cholesterol (LDL) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · mmol/L
Change From Baseline in Lipids - LDL Cholesterol
mmol/LLiraglutide 3.0 mgPlacebo
Change From Baseline in Lipids - LDL Cholesterol-0.01 ± 0.52-0.01 ± 0.64
SecondaryChange From Baseline in Lipids - HDL Cholesterol

Observed mean change from baseline in high density (HDL) cholesterol from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · mmol/L
Change From Baseline in Lipids - HDL Cholesterol
mmol/LLiraglutide 3.0 mgPlacebo
Change From Baseline in Lipids - HDL Cholesterol0.06 ± 0.190.02 ± 0.22
SecondaryChange From Baseline in Lipids - VLDL Cholesterol

Observed mean change from baseline in very low density cholesterol (VLDL) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · mmol/L
Change From Baseline in Lipids - VLDL Cholesterol
mmol/LLiraglutide 3.0 mgPlacebo
Change From Baseline in Lipids - VLDL Cholesterol-0.06 ± 0.31-0.01 ± 0.26
SecondaryChange From Baseline in Lipids - TG

Observed mean change from baseline in triglyceride (TG) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · mmol/L
Change From Baseline in Lipids - TG
mmol/LLiraglutide 3.0 mgPlacebo
Change From Baseline in Lipids - TG-0.19 ± 1.04-0.01 ± 0.58
SecondaryChange From Baseline in Lipids - FFA

Observed mean change from baseline in free fatty acids (FFA) from baseline (week 0) to week 56. Results based on FAS in-trial data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · mmol/L
Change From Baseline in Lipids - FFA
mmol/LLiraglutide 3.0 mgPlacebo
Change From Baseline in Lipids - FFA-0.07 ± 0.28-0.06 ± 0.31
SecondaryChange in Short Form-36 v2.0 Acute (SF-36) (Subdomains)

SF-36 is a 36-item patient-reported survey of patient health that measures the subject's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in in the sub-domain scores is presented. A positive change score indicates an improvement since baseline. Results are evaluated based on in-trial data.

Time frame:
Week 0, week 56
Reported as:
Mean · scores on a scale
Change in Short Form-36 v2.0 Acute (SF-36) (Subdomains)
scores on a scaleLiraglutide 3.0 mgPlacebo
Bodily Pain0.67 ± 7.611.21 ± 8.88
General Health Perception1.89 ± 6.311.08 ± 6.62
Mental Health-0.93 ± 7.80-0.68 ± 6.89
Role Lim Emotion Prob-1.27 ± 7.72-2.21 ± 8.59
Role Lim. Phy Health2.01 ± 6.552.11 ± 7.68
Social Functioning1.22 ± 8.69-0.45 ± 9.61
Vitality2.64 ± 8.992.43 ± 7.78
SecondaryChange in Short Form-36 v2.0 Acute (SF-36) (Physical Component Summary (PCS))

Observed mean change from baseline (week 0) to week 56 in short form 36 v2.0 acute domain physical component summary (PCS). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in SF-36 physical component summary (PCS) score is presented. A positive change score indicates an improvement since baseline. The endpoint was evaluated based on in-trial data and on-drug data.

Time frame:
Week 0, week 56
Reported as:
Mean · scores on a scale
Change in Short Form-36 v2.0 Acute (SF-36) (Physical Component Summary (PCS))
scores on a scaleLiraglutide 3.0 mgPlacebo
Change in Short Form-36 v2.0 Acute (SF-36) (Physical Component Summary (PCS))3.41 ± 6.653.83 ± 7.22
SecondaryChange in Short Form-36 v2.0 Acute (SF-36) (Mental Component Summary (MCS)

Observed mean change from baseline (week 0) to week 56 in short form 36 v2.0 acute domain mental component summary (MCS). SF-36v2™ questionnaire measured the HRQoL on 8 domains on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. Change from baseline in SF-36 mental component summary is presented. A positive change score indicates an improvement since baseline. The endpoint was evaluated based on in-trial data and on-drug data.

Time frame:
Week 0, week 56
Reported as:
Mean · scores on a scale
Change in Short Form-36 v2.0 Acute (SF-36) (Mental Component Summary (MCS)
scores on a scaleLiraglutide 3.0 mgPlacebo
Change in Short Form-36 v2.0 Acute (SF-36) (Mental Component Summary (MCS)-1.22 ± 8.74-2.20 ± 8.11
SecondaryChange in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Pain/Discomfort Domain Score

Observed mean change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT) domain pain and discomfort. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. Results based on FAS in-trial data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · scores on a scale
Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Pain/Discomfort Domain Score
scores on a scaleLiraglutide 3.0 mgPlacebo
Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Pain/Discomfort Domain Score10.1 ± 21.28.6 ± 23.1
SecondaryChange in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Psychosocial Domain Score

Observed mean change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT) psychosocial domain. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. Results based on FAS in-trial data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · score
Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Psychosocial Domain Score
scoreLiraglutide 3.0 mgPlacebo
Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Psychosocial Domain Score13.5 ± 20.312.4 ± 21.8
SecondaryChange in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Total Score

Observed mean change from baseline (week 0) to week 56 in IWQoL-Lite for CT total score. IWQoL-Lite for CT (Weight on Quality of Life-Lite for Clinical Trial Version) is a modified version of an instrument designed to assess weight-related quality of life. The scores ranged between 0-100 where higher scores indicated a better quality of life. A positive change score indicates an improvement since baseline. Results based on FAS in-trial data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · scores on a scale
Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Total Score
scores on a scaleLiraglutide 3.0 mgPlacebo
Change in Impact of Weight on Quality of Life-Lite for Clinical Trial Version (IWQoL-Lite for CT): Total Score13.2 ± 18.512.8 ± 20.7
SecondaryChange in Weight Related Sign and Symptom (WRSS) Measure, Total Score

Observed mean change from baseline (week 0) to week 56 in WRSS measure, total score. The WRSS measures the presence and bothersome associated with weight-related symptoms. The WRSS questionnaire was not validated until after database lock. Therefore the total score couldn't be calculated and the supportive secondary endpoint "Weight related sign and symptom (WRSS) measure, total score" couldn't be analysed.

Time frame:
Week 0, week 56
Reported as:
Mean · Score on a scale
Change in Weight Related Sign and Symptom (WRSS) Measure, Total Score
Score on a scaleLiraglutide 3.0 mgPlacebo
Change in Weight Related Sign and Symptom (WRSS) Measure, Total ScoreNA ± NANA ± NA
SecondarySubjects Who After 56 Weeks Achieve (Yes/no): ≥ 4.3 T-score Points Increase From Baseline in SF-36 Physical Functioning Score

Percentage of subjects who achieved ≥ 4.3 T-score points increase from baseline in SF-36 physical functioning score at week 56 is presented. Results based on FAS in-trial data is presented.

Time frame:
Week 56
Reported as:
Number · percentage of participants
Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 4.3 T-score Points Increase From Baseline in SF-36 Physical Functioning Score
percentage of participantsLiraglutide 3.0 mgPlacebo
Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 4.3 T-score Points Increase From Baseline in SF-36 Physical Functioning Score38.737.9
SecondarySubjects Who After 56 Weeks Achieve (Yes/no): ≥ 3.8 T-score Points Increase From Baseline in SF-36 Physical Component Score

Percentage of subjects who achieved ≥ 3.8 T-score points increase from baseline in SF-36 physical component score at week 56 is presented. Results based on FAS in-trial data is presented.

Time frame:
Week 56
Reported as:
Number · Percentage of participants
Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 3.8 T-score Points Increase From Baseline in SF-36 Physical Component Score
Percentage of participantsLiraglutide 3.0 mgPlacebo
Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 3.8 T-score Points Increase From Baseline in SF-36 Physical Component Score43.741.4
SecondarySubjects Who After 56 Weeks Achieve (Yes/no): ≥ 4.6 T-score Points Increase From Baseline in SF-36 Mental Component Score

Percentage of subjects who achieved ≥ 4.6 T-score points increase from baseline in SF-36 mental component score at week 56 is presented. Results based on FAS in-trial data is presented.

Time frame:
Week 56
Reported as:
Number · Percentage of participants
Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 4.6 T-score Points Increase From Baseline in SF-36 Mental Component Score
Percentage of participantsLiraglutide 3.0 mgPlacebo
Subjects Who After 56 Weeks Achieve (Yes/no): ≥ 4.6 T-score Points Increase From Baseline in SF-36 Mental Component Score20.49.3
SecondaryResponder Definition Value for IWQoL-Lite for CT Physical Function Domain (5-items) Score

Responder definition value for IWQoL-Lite for CT physical function domain (5-items) score' was defined as '≥ 20 responder definition value for IWQoL-Lite for CT physical function domain (5-items) score. Percentage of subjects considered IWQoL-Lite for CT physical function domain score responders (increase of ≥20 points) at week 56 is presented. Results based on FAS in-trial data is presented.

Time frame:
Week 56
Reported as:
Number · Percentage of participants
Responder Definition Value for IWQoL-Lite for CT Physical Function Domain (5-items) Score
Percentage of participantsLiraglutide 3.0 mgPlacebo
Responder Definition Value for IWQoL-Lite for CT Physical Function Domain (5-items) Score37.334.3
SecondaryNumber of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Trial Product

Adherence to trial product is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to trial product is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · weeks
Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Trial Product
weeksLiraglutide 3.0 mgPlacebo
Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Trial Product49.5 ± 14.046.8 ± 16.1
SecondaryNumber of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet

Adherence to caloric diet is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to caloric diet is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · weeks
Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet
weeksLiraglutide 3.0 mgPlacebo
Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet38.4 ± 16.036.1 ± 17.3
SecondaryNumber of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Physical Activity

Adherence to physical activity is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to physical activity is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · weeks
Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Physical Activity
weeksLiraglutide 3.0 mgPlacebo
Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Physical Activity29.0 ± 17.130.0 ± 17.2
SecondaryNumber of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet and Physical Activity

Adherence to caloric diet and physical activity is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to caloric diet and physical activity is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · weeks
Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet and Physical Activity
weeksLiraglutide 3.0 mgPlacebo
Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet and Physical Activity24.0 ± 16.024.5 ± 15.7
SecondaryNumber of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet, Physical Activity and Trial Product

Adherence to caloric diet, physical activity and trial product is assessed regularly at CMS-IBT visits. The number of weeks from randomisation to week 56, adherent to caloric diet, physical activity and trial product is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · weeks
Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet, Physical Activity and Trial Product
weeksLiraglutide 3.0 mgPlacebo
Number of Weeks (Completed Calendar Weeks) From Randomisation to Week 56 Adherent to Caloric Diet, Physical Activity and Trial Product22.9 ± 16.124.0 ± 15.9
SecondaryAEs From Randomisation Until and Including the Follow-up Period

Number of adverse events from randomisation to until the end of the post-treatment follow-up period (30 days). Results based on SAS on-drug data is presented.

Time frame:
Week 0 to week 56+30 days
Reported as:
Number · events
AEs From Randomisation Until and Including the Follow-up Period
eventsLiraglutide 3.0 mgPlacebo
AEs From Randomisation Until and Including the Follow-up Period867601
SecondaryChange in Physical Examination

Observed change from baseline to week 56 in physical examination are categorised under parameters namely abdomen, gastrointestinal system, cardiovascular system, central and peripheral nervous system, general appearence, head, ears, eyes, nose, throat and neck, lymph node palpation, musculoskeletal system, respiratory system, skin and thyroid gland. The percentage of subjects assessed as normal, abnormal not clinically significant and abnormal clinically significant at baseline and week 56 is presented.

Time frame:
Week 1, week 56
Reported as:
Number · participants
Change in Physical Examination
participantsLiraglutide 3.0 mgPlacebo
Abdomen (week -1) Normal108121
Abdomen (week -1) Abnormal, NCS3419
Abdomen (week -1) Abnormal CS00
Abdomen (week 56) Normal114108
Abdomen (week 56) Abnormal, NCS2512
Abdomen (week 56) Abnormal, CS02
Gastrointestinal System (week -1) Normal130129
Gastrointestinal System (week -1) Abnormal NCS1211
Gastrointestinal System (week -1) Abnormal CS00
Gastrointestinal System (week 56) Normal132116
Gastrointestinal System (week 56) Abnormal NCS76
Gastrointestinal System (week 56) Abnormal CS00
Cardiovascular System (week-1) Normal136127
Cardiovascular System (week-1) Abnormal NCS613
Cardiovascular System (week-1) Abnormal CS00
Cardiovascular System (week 56) Normal138116
Cardiovascular System (week 56) Abnormal NCS15
Cardiovascular System (week 56) Abnormal CS01
Nervous System (week -1) Normal135127
Nervous System (week -1) Abnormal NCS56
Nervous System (week -1) Abnormal CS27
Nervous System (week 56) Normal132112
Nervous System (week 56) Abnormal NCS69
Nervous System (week 56) Abnormal CS11
General Appearance (week -1) Normal118123
General Appearance (week -1) Abnormal NCS2417
General Appearance (week -1) Abnormal CS00
General Appearance (week 56) Normal122112
General Appearance (week 56) Abnormal NCS1710
General Appearance (week 56) Abnormal CS00
Head, ENTand Neck (week -1) Normal129128
Head, ENTand Neck (week -1) Abnormal NCS1312
Head, ENTand Neck (week -1) Abnormal CS00
Head, ENTand Neck (week 56) Normal126115
Head, ENTand Neck (week 56) Abnormal NCS137
Head, ENTand Neck (week 56) Abnormal CS00
Lymph Node Palpation (week -1) Normal142140
Lymph Node Palpation (week -1) Abnormal NCS00
Lymph Node Palpation (week -1) Abnormal CS00
Lymph Node Palpation (week 56) Normal139121
Lymph Node Palpation (week 56) Abnormal NCS00
Lymph Node Palpation (week 56) Abnormal CS01
Musculoskeletal System (week -1) Normal131128
Musculoskeletal System (week -1) Abnormal NCS1112
Musculoskeletal System (week -1) Abnormal CS00
Musculoskeletal System (week 56) Normal130112
Musculoskeletal System (week 56) Abnormal NCS99
Musculoskeletal System (week 56) Abnormal CS01
Respiratory System (week -1) Normal140138
Respiratory System (week -1) Abnormal NCS22
Respiratory System (week -1) Abnormal CS00
Respiratory System (week 56) Normal138120
Respiratory System (week 56) Abnormal NCS12
Respiratory System (week 56) Abnormal CS00
Skin (week -1) Normal116114
Skin (week -1) Abnormal NCS2624
Skin (week -1) Abnormal CS10
Skin (week 56) Normal11798
Skin (week 56) Abnormal NCS2124
Skin (week 56) Abnormal CS10
Thyroid Gland (week -1) Normal138138
Thyroid Gland (week -1) Abnormal NCS42
Thyroid Gland (week -1) Abnormal CS00
Thyroid Gland (week 56) Normal136120
Thyroid Gland (week 56) Abnormal NCS32
Thyroid Gland (week 56) Abnormal CS00
SecondaryChange in Resting Pulse

Observed mean change in pulse rate measured at resting position is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · beats/min
Change in Resting Pulse
beats/minLiraglutide 3.0 mgPlacebo
Change in Resting Pulse2 ± 101 ± 10
SecondaryChange in ECG

The ECGs were interpreted by the investigator at baseline (week -1) and week 56 and categorised as normal, abnormal NCS or abnormal CS. Number of subjects in each ECG category at baseline and week 56 are presented.

Time frame:
Week -1, week 56
Reported as:
Number · participants
Change in ECG
participantsLiraglutide 3.0 mgPlacebo
Normal (week -1)10091
Abnormal NCS (week -1)4149
Abnormal CS (week -1)10
Normal (week 56)10281
Abnormal NCS (week 56)3642
Abnormal CS (week 56)01
SecondaryChange in Laboratory Measurements: Haematology (Haemoglobin Blood)

Observed mean change from baseline in haematological parameter blood haemoglobin.

Time frame:
Week 0, week 56
Reported as:
Mean · mmol/L
Change in Laboratory Measurements: Haematology (Haemoglobin Blood)
mmol/LLiraglutide 3.0 mgPlacebo
Change in Laboratory Measurements: Haematology (Haemoglobin Blood)-0.2 ± 0.5-0.1 ± 0.6
SecondaryChange in Laboratory Measurements: Haematology (Haematocrit Blood)

Observed mean change from baseline in haematological parameter blood haematocrit. Haematocrit is presented as the percentage of red blood cells in total blood. Results based on SAS on-drug data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · percentage of red blood cells
Change in Laboratory Measurements: Haematology (Haematocrit Blood)
percentage of red blood cellsLiraglutide 3.0 mgPlacebo
Change in Laboratory Measurements: Haematology (Haematocrit Blood)-1.5 ± 2.3-0.9 ± 2.6
SecondaryChange in Laboratory Measurements: Haematology (Erythrocytes)

Observed mean change from baseline in haematological parameter - erythrocytes.

Time frame:
Week 0, week 56
Reported as:
Mean · 10^12 cells/L
Change in Laboratory Measurements: Haematology (Erythrocytes)
10^12 cells/LLiraglutide 3.0 mgPlacebo
Change in Laboratory Measurements: Haematology (Erythrocytes)-0.11 ± 0.25-0.08 ± 0.25
SecondaryChange in Laboratory Measurements: Haematology (Thrombocytes and Leukocytes)

Observed mean change from baseline in haematological parameters - thrombocytss and leukocytes.

Time frame:
Week 0, week 56
Reported as:
Mean · 10^9 cells/L
Change in Laboratory Measurements: Haematology (Thrombocytes and Leukocytes)
10^9 cells/LLiraglutide 3.0 mgPlacebo
Thrombocytes4 ± 300 ± 36
Leukocytes-0.14 ± 1.53-0.11 ± 1.20
SecondaryChange in Laboratory Measurements: Biochemistry (Albumin)

Observed mean change from baseline in biochemical parameter - albumin. Results based on SAS on-drug data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · g/L
Change in Laboratory Measurements: Biochemistry (Albumin)
g/LLiraglutide 3.0 mgPlacebo
Change in Laboratory Measurements: Biochemistry (Albumin)-0.1 ± 0.2-0.1 ± 0.2
SecondaryChange in Laboratory Measurements: Biochemistry (Alkaline Phosphatase, Alanine Aminotransferase, Amylase, Aspartate Aminotransferase and Lipase)

Observed mean change from baseline in biochemical parameters - alkaline phosphatase, alanine aminotransferase, amylase, aspartate aminotransferase and lipase. Results based on SAS on-drug data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · U/L
Change in Laboratory Measurements: Biochemistry (Alkaline Phosphatase, Alanine Aminotransferase, Amylase, Aspartate Aminotransferase and Lipase)
U/LLiraglutide 3.0 mgPlacebo
Alkaline Phosphatase-2 ± 12-1 ± 13
Alanine Aminotransferase-5 ± 14-4 ± 16
Amylase4 ± 101 ± 13
Aspartate aminotransferase-3 ± 10-2 ± 12
Lipase7 ± 182 ± 22
SecondaryChange in Laboratory Measurements: Biochemistry (Bilirubin and Creatinine)

Observed mean change from baseline in biochemical parameters - bilirubin and creatinine. Results based on SAS on-drug data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · umol/L
Change in Laboratory Measurements: Biochemistry (Bilirubin and Creatinine)
umol/LLiraglutide 3.0 mgPlacebo
Bilirubin1.1 ± 3.21.0 ± 3.2
Creatinine-1.8 ± 7.9-1.4 ± 6.1
SecondaryChange in Laboratory Measurements: Biochemistry (Total Calcium, Pottassium, Sodium and Urea)

Observed mean change from baseline in biochemical parameters - total calcium, pottassium, sodium and urea. Results based on SAS on-drug data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · mmol/L
Change in Laboratory Measurements: Biochemistry (Total Calcium, Pottassium, Sodium and Urea)
mmol/LLiraglutide 3.0 mgPlacebo
Total Calcium0.01 ± 0.100.01 ± 0.09
Potassium-0.0 ± 0.5-0.0 ± 0.4
Sodium-0.0 ± 2-0 ± 2
Urea0.0 ± 1.20.2 ± 1.2
SecondaryChange in Laboratory Measurements: Biochemistry (C-reactive Protein and Uric Acid)

Observed mean change from baseline in biochemical parameters - high sensitive c-reactive protein and uric acid. Results based on SAS on-drug data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · mg/dL
Change in Laboratory Measurements: Biochemistry (C-reactive Protein and Uric Acid)
mg/dLLiraglutide 3.0 mgPlacebo
High sensitive c-reactive protein-2.51 ± 4.67-0.85 ± 8.96
Uric acid-0.6 ± 0.9-0.3 ± 0.9
SecondaryChange in Laboratory Measurements: Biochemistry (Glomerular Filtration Rate, Serum)

Observed mean change from baseline in biochemical parameters - estimated glomerular filtration rate. Serum GFR is estimated using MDRD formula . Results based on SAS on-drug data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · mL/min/1.73m^2
Change in Laboratory Measurements: Biochemistry (Glomerular Filtration Rate, Serum)
mL/min/1.73m^2Liraglutide 3.0 mgPlacebo
Change in Laboratory Measurements: Biochemistry (Glomerular Filtration Rate, Serum)2 ± 112 ± 9
SecondaryChange in Laboratory Measurements: Biochemistry (Calcitonin)

Observed mean change from baseline in biochemical parameter - calcitonin. Results based on SAS on-drug data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · ng/L
Change in Laboratory Measurements: Biochemistry (Calcitonin)
ng/LLiraglutide 3.0 mgPlacebo
Change in Laboratory Measurements: Biochemistry (Calcitonin)0.2 ± 0.80.1 ± 0.8
SecondaryChange in Laboratory Measurements: Biochemistry (Thyroid Stimulating Hormone)

Observed mean change from baseline in biochemical parameters - thyroid stimulating hormone. Results based on SAS on-drug data is presented.

Time frame:
Week 0, week 56
Reported as:
Mean · mIU/L
Change in Laboratory Measurements: Biochemistry (Thyroid Stimulating Hormone)
mIU/LLiraglutide 3.0 mgPlacebo
Change in Laboratory Measurements: Biochemistry (Thyroid Stimulating Hormone)-0.2313 ± 1.03660.2685 ± 3.6814

Adverse events

Collected over From the date of first dose of trial product (week 0) to end of treatment (week 56) + post treatment follow-up of 30 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lira 3.0 mg0/142 (0%)6/142 (4.2%)124/142 (87.3%)
Placebo0/140 (0%)2/140 (1.4%)101/140 (72.1%)
Most frequent serious events
Most frequent serious events
EventLira 3.0 mgPlacebo
Ankle fractureInjury, poisoning and procedural complications0/1421/140
HydrocephalusNervous system disorders0/1421/140
Cholecystitis acuteHepatobiliary disorders1/1420/140
ColitisGastrointestinal disorders1/1420/140
HeadacheNervous system disorders1/1420/140
OsteoarthritisMusculoskeletal and connective tissue disorders1/1420/140
Ovarian cystReproductive system and breast disorders1/1420/140
Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1420/140
Most frequent other events
Showing 10 of 22
Most frequent other events
EventLira 3.0 mgPlacebo
NauseaGastrointestinal disorders68/14225/140
ConstipationGastrointestinal disorders43/14226/140
VomitingGastrointestinal disorders33/1427/140
Upper respiratory tract infectionInfections and infestations32/14215/140
DiarrhoeaGastrointestinal disorders31/14223/140
HeadacheNervous system disorders20/14213/140
SinusitisInfections and infestations9/14218/140
ArthralgiaMusculoskeletal and connective tissue disorders9/14216/140
Back painMusculoskeletal and connective tissue disorders8/14213/140
InfluenzaInfections and infestations5/14213/140

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Liraglutide 3.0 mgPlaceboTotal
Mean45.4 ± 11.649 ± 11.247.2 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Liraglutide 3.0 mgPlaceboTotal
Female119116235
Male232447
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Liraglutide 3.0 mgPlaceboTotal
American Indian or Alaska Native000
Asian235
Native Hawaiian or Other Pacific Islander101
Black or African American272249
White112115227
More than one race000
Unknown or Not Reported000
Body weight
Body weight(kg)Liraglutide 3.0 mgPlaceboTotal
Mean108.5 ± 22.1106.7 ± 22.0107.6 ± 22.0
09

Study locations

10 sites
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32205, United States
  • Novo Nordisk Investigational Site
    Plantation, Florida 33324, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60607, United States
  • Novo Nordisk Investigational Site
    Greensboro, North Carolina 27408, United States
  • Novo Nordisk Investigational Site
    Salisbury, North Carolina 28144, United States
  • Novo Nordisk Investigational Site
    Wadsworth, Ohio 44281, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19104-3317, United States
  • Novo Nordisk Investigational Site
    Charleston, South Carolina 29425, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75251, United States
  • Novo Nordisk Investigational Site
    Arlington, Virginia 22206, United States
10

References and documents

Publications

  • Wadden TA, Tronieri JS, Sugimoto D, Lund MT, Auerbach P, Jensen C, Rubino D. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial. Obesity (Silver Spring). 2020 Mar;28(3):529-536. doi: 10.1002/oby.22726. PubMed 32090517 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in May 2018, 15 months.

Results were first posted in Jul 2019, 1 year 2 months after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 15 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2016
First posted
Nov 15, 2016
StartActual
Feb 6, 2017
Primary completionActual
May 23, 2018
CompletionActual
Jun 19, 2018
Results first posted
Jul 30, 2019
Last update
Mar 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02963935
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 15, 2016
Start date
Feb 6, 2017
Primary completion
May 23, 2018
Completion
Jun 19, 2018
Results posted
Jul 30, 2019
Last update
Mar 11, 2020

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion